| Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update |
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- |
globenewswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors |
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. |
globenewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Stock Plummets 56% in a Month: Here's the Reason |
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants. |
zacks.com |
2025-04-10 18:10:40 |
Czytaj oryginał (ang.) |
| Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. |
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary. |
zacks.com |
2025-04-01 12:25:34 |
Czytaj oryginał (ang.) |
| Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity |
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it. |
seekingalpha.com |
2025-03-31 19:39:08 |
Czytaj oryginał (ang.) |
| Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine |
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's PFE Prevnar 20 (PCV20) in healthy infants. |
benzinga.com |
2025-03-31 12:56:13 |
Czytaj oryginał (ang.) |
| Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study |
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formulation for Advancement to Potential Infant Phase 3 Program, Pending Topline VAX-31 Infant Phase 2 Study Readout -- -- Company Announces VAX-XL, Third-Generation PCV Candidate Designed to Further Expand Spectrum of Coverage -- -- Company to Host Webcast/Conference Call Today at 8:00 a.m. ET / 5:00 a.m. |
globenewswire.com |
2025-03-31 11:00:00 |
Czytaj oryginał (ang.) |
| Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study |
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. |
globenewswire.com |
2025-03-30 21:00:00 |
Czytaj oryginał (ang.) |
| Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript |
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus Fernandez - Guggenheim Tom Shrader - BTIG Joseph Stringer - Needham & Company Operator Good afternoon, my name is Jess, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full Year 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-02-26 05:26:18 |
Czytaj oryginał (ang.) |
| Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series of VAX-24 Infant Phase 2 Study by the End of First Quarter, Followed by Topline Data from Booster Dose by the End of 2025 -- |
globenewswire.com |
2025-02-25 18:01:00 |
Czytaj oryginał (ang.) |
| Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 |
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. |
globenewswire.com |
2025-02-12 18:05:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants |
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- |
globenewswire.com |
2025-02-05 10:00:00 |
Czytaj oryginał (ang.) |
| Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference |
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT. |
globenewswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm |
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. |
globenewswire.com |
2025-01-30 13:51:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy |
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with over $3 billion in cash and investments, supports its strategic flexibility and extended timelines. |
seekingalpha.com |
2025-01-15 09:15:20 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm |
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-07 03:13:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm |
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. |
globenewswire.com |
2024-12-19 14:16:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants |
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- |
globenewswire.com |
2024-12-03 10:00:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs |
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 -- |
globenewswire.com |
2024-11-12 09:30:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update |
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 -- |
globenewswire.com |
2024-11-05 18:01:00 |
Czytaj oryginał (ang.) |
| Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference |
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT. |
globenewswire.com |
2024-09-11 20:05:00 |
Czytaj oryginał (ang.) |
| Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027 |
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025. |
seekingalpha.com |
2024-09-08 13:00:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares |
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte. |
globenewswire.com |
2024-09-06 20:05:00 |
Czytaj oryginał (ang.) |
| Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy |
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market. |
seekingalpha.com |
2024-09-06 19:07:13 |
Czytaj oryginał (ang.) |
| Vaxcyte's stock dips after biotech completes $1.42 billion stock offering |
Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds. |
marketwatch.com |
2024-09-06 13:07:00 |
Czytaj oryginał (ang.) |
| Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high |
Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial. |
reuters.com |
2024-09-05 05:22:14 |
Czytaj oryginał (ang.) |
| Vaxcyte Announces Pricing of $1.3 Billion Public Offering |
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. |
globenewswire.com |
2024-09-05 03:58:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results |
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck. |
zacks.com |
2024-09-04 15:56:09 |
Czytaj oryginał (ang.) |
| Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants |
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of $1.0 billion of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $150.0 million of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-09-03 20:01:00 |
Czytaj oryginał (ang.) |
| Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower |
Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older. |
schaeffersresearch.com |
2024-09-03 18:10:03 |
Czytaj oryginał (ang.) |
| Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. |
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's. |
barrons.com |
2024-09-03 14:48:00 |
Czytaj oryginał (ang.) |
| Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine |
Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to rival Pfizer's shot. |
reuters.com |
2024-09-03 13:24:43 |
Czytaj oryginał (ang.) |
| Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market |
Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine. |
investors.com |
2024-09-03 13:07:04 |
Czytaj oryginał (ang.) |
| Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine |
Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older. |
marketwatch.com |
2024-09-03 12:51:00 |
Czytaj oryginał (ang.) |
| Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older |
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes -- |
globenewswire.com |
2024-09-03 11:07:00 |
Czytaj oryginał (ang.) |
| Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older |
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older. |
globenewswire.com |
2024-09-02 22:40:00 |
Czytaj oryginał (ang.) |